EUVIMEDEUVIMED entdecken
Vergleichsstudie

Ethnic Bridging of Votoplam, a HTT Gene Splicing Modifier, Using Pharmacokinetic Comparison Between Caucasian and Japanese Subjects

Lucy Lee, Amy-Lee Richards, Prachi Anand, Brian Beers, Lee Golden, Ronald Kong

Clinical Pharmacology in Drug Development · 2026-05 · 15 (5)

DOI: 10.1002/cpdd.70062 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 30.04.2026. Verfasst von Lucy Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: PTC Therapeutics, Inc., Warren, NJ, USA. Hauptthemen laut MEDLINE: Huntingtin Protein, White People. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Votoplam is a novel, orally bioavailable, small molecule HTT gene splicing modifier that is being developed for the treatment of Huntington's disease. A single‐dose, open‐label, three‐dose level (5, 10, 20 mg), parallel group ethnicity study was conducted to evaluate the pharmacokinetics and safety of votoplam in healthy Caucasian versus Japanese participants. Six participants per ethnic group were enrolled at each dose (12 participants per dose level overall). Thirty‐five participants (N = 18 Japanese; N = 17 Caucasian) completed the study. Study results showed slightly higher exposure for Japanese participants at all dose levels. AUC 0–last increased by 1.27‐, 1.17‐, and 1.29‐fold, and C max increased by 1.58‐, 1.19‐, and 1.61‐fold for 5, 10, and 20 mg, respectively, for Japanese compared with Caucasian participants. Doses proportionality was observed for both ethnicities. Few mild and moderate TEAEs were reported and were comparable between Japanese and Caucasian participants. In summary, votoplam pharmacokinetics and safety profiles are similar between healthy Japanese and Caucasian participants when administered in the single dose range of 5, 10, and 20 mg. Therefore, it is expected that dose adjustments should not be necessary in future clinical studies enrolling Japanese participants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntingtin ProteinWhite PeopleAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralArea Under CurveDose-Response Relationship, DrugJapanEast Asian People

Stichwörter der Autor:innen

Huntington's diseaseethnic bridginghealthy volunteerspharmacokineticrare disease

Substanzen

HTT protein, humanHuntingtin Protein

Autor:innen und Institutionen

  • PTC Therapeutics, Inc., Warren, NJ, USA.

Zitieren

APA

Lee, L., Richards, A. L., Anand, P., Beers, B., Golden, L., & Kong, R. (2026). Ethnic Bridging of Votoplam, a HTT Gene Splicing Modifier, Using Pharmacokinetic Comparison Between Caucasian and Japanese Subjects. Clinical Pharmacology in Drug Development, 15(5). https://doi.org/10.1002/cpdd.70062

Vancouver

Lee L, Richards AL, Anand P, Beers B, Golden L, Kong R. Ethnic Bridging of Votoplam, a HTT Gene Splicing Modifier, Using Pharmacokinetic Comparison Between Caucasian and Japanese Subjects. Clinical Pharmacology in Drug Development. 2026;15(5). doi:10.1002/cpdd.70062

BibTeX
@article{Lee2026,
  author = {Lee, Lucy and Richards, Amy-Lee and Anand, Prachi and Beers, Brian and Golden, Lee and Kong, Ronald},
  title = {Ethnic Bridging of Votoplam, a HTT Gene Splicing Modifier, Using Pharmacokinetic Comparison Between Caucasian and Japanese Subjects},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cpdd.70062}
}
Kostenlos starten →